Literature DB >> 30182193

[Catheter-based atrial appendage closure-current data and future developments].

C Skurk1,2, J J Hartung1,2, D M Leistner1,2,3, U Landmesser4,5,6.   

Abstract

In Germany more than 1.6 million patients suffer from atrial fibrillation (AF). Within the next decades this number will substantially increase due to current demographic trends with the increasing average age of the population. When untreated, patients with atrial fibrillation have a five times higher risk for stroke as compared with a control cohort. A potent stroke prevention therapy reducing the risk of stroke by approximately 70-80% is primarily treatment with new oral anticoagulants (NOACs). The risk scores for stroke (CHA2DS2-VASc) and major bleeding (HAS-BLED) in patients with atrial fibrillation share common variables, so that patients with the highest stroke risk often carry a very high bleeding risk. A significant number of patients (ca. 20-30%) are, however, not eligible for long-term anticoagulation, e.g. because of a high bleeding risk. For this population there is an urgent need for alternative stroke prevention strategies, such as catheter-based percutaneous left atrial appendage closure. Current data about the efficiency and safety of this treatment as well as a discussion of ongoing recruitment for randomized studies are discussed in this review.

Entities:  

Keywords:  Anticoagulants; Atrial fibrillation; Hemorrhage; Stroke prevention; Vitamin K antagonists

Mesh:

Substances:

Year:  2018        PMID: 30182193     DOI: 10.1007/s00108-018-0483-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  19 in total

1.  Short-term dual antiplatelet therapy after interventional left atrial appendage closure with different devices.

Authors:  Felix K Weise; Stefano Bordignon; Laura Perrotta; Athanasios Konstantinou; Fabrizio Bologna; Takahiko Nagase; Shaojie Chen; K R Julian Chun; Boris Schmidt
Journal:  EuroIntervention       Date:  2018-04-06       Impact factor: 6.534

2.  Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry.

Authors:  Ulf Landmesser; Claudio Tondo; John Camm; Hans-Christoph Diener; Vince Paul; Boris Schmidt; Magnus Settergren; Emmanuel Teiger; Jens Erik Nielsen-Kudsk; David Hildick-Smith
Journal:  EuroIntervention       Date:  2018-08-03       Impact factor: 6.534

3.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.

Authors:  Gregory Y H Lip; Lars Frison; Jonathan L Halperin; Deirdre A Lane
Journal:  J Am Coll Cardiol       Date:  2010-11-24       Impact factor: 24.094

4.  Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation.

Authors:  Miney Paquette; Lionel Riou França; Christine Teutsch; Hans-Christoph Diener; Shihai Lu; Sergio J Dubner; Chang Sheng Ma; Kenneth J Rothman; Kristina Zint; Jonathan L Halperin; Menno V Huisman; Gregory Y H Lip; Robby Nieuwlaat
Journal:  J Am Coll Cardiol       Date:  2017-09-26       Impact factor: 24.094

5.  Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study.

Authors:  Ulf Landmesser; Boris Schmidt; Jens Erik Nielsen-Kudsk; Simon Cheung Chi Lam; Jai-Wun Park; Giuseppe Tarantini; Ignacio Cruz-Gonzalez; Volker Geist; Paolo Della Bella; Antonio Colombo; Tobias Zeus; Heyder Omran; Christopher Piorkowski; Juha Lund; Claudio Tondo; David Hildick-Smith
Journal:  EuroIntervention       Date:  2017-09-20       Impact factor: 6.534

6.  Thrombus Formation After Left Atrial Appendage Occlusion With the Amplatzer Amulet Device.

Authors:  Alexander Sedaghat; Jan-Wilko Schrickel; René Andrié; Robert Schueler; Georg Nickenig; Christoph Hammerstingl
Journal:  JACC Clin Electrophysiol       Date:  2016-07-27

7.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.

Authors:  David R Holmes; Saibal Kar; Matthew J Price; Brian Whisenant; Horst Sievert; Shephal K Doshi; Kenneth Huber; Vivek Y Reddy
Journal:  J Am Coll Cardiol       Date:  2014-07-08       Impact factor: 24.094

8.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.

Authors:  David R Holmes; Vivek Y Reddy; Zoltan G Turi; Shephal K Doshi; Horst Sievert; Maurice Buchbinder; Christopher M Mullin; Peter Sick
Journal:  Lancet       Date:  2009-08-15       Impact factor: 79.321

9.  5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.

Authors:  Vivek Y Reddy; Shephal K Doshi; Saibal Kar; Douglas N Gibson; Matthew J Price; Kenneth Huber; Rodney P Horton; Maurice Buchbinder; Petr Neuzil; Nicole T Gordon; David R Holmes
Journal:  J Am Coll Cardiol       Date:  2017-11-04       Impact factor: 24.094

10.  Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care.

Authors:  Michelle E Johnson; Cinira Lefèvre; Shuk-Li Collings; David Evans; Sebastian Kloss; Essra Ridha; Andrew Maguire
Journal:  BMJ Open       Date:  2016-09-26       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.